HIV vaccine - Institute of Human Virology/Profectus Biosciences

Drug Profile

HIV vaccine - Institute of Human Virology/Profectus Biosciences

Alternative Names: AIM Therapy - Profectus BioScience; anti-HIV antibodies - Profectus BioScience; FLSC vaccine; Full-length single chain vaccine; IHV 001; IHV 01

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Profectus Biosciences
  • Developer Institute of Human Virology; Profectus Biosciences
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 01 Oct 2015 Phase-I clinical trials in HIV infections (In volunteers, Prevention) in USA (Parenteral) (9185545; NCT02756208)
  • 19 Jul 2007 Profectus BioSciences receives SBIR grant from National Institute of Allergy and Infectious Diseases for Anti-HIV antibodies development in HIV infections
  • 19 Jul 2007 Preclinical trials in HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top